论文部分内容阅读
自身干细胞移植(AHSCT)治疗恶性淋巴瘤于1978年首次报道。目前,自身末梢血干细胞移植(PBSCT)正在成为AHSCT的主流,因PBSCT在安全性、医疗费等方面,均优于自身骨髓移植(ABMT)。 AHSCT对中度恶性非霍奇金淋巴瘤(NHL),据报道初次缓解(CR_1)有55％～80％的无病生存率(DFS),对化疗敏感复发的DFS是30％～50％,而化疗不敏感组DFS在15％以下。作者回顾福岡骨髓移植组中度恶性NHL33例,施行PBSCT,其中CR_1 9例,CR_2 8例,复发/化疗不敏感16例,2年DFS分别是75％,49％,33％,正继续观察远期效果。高度恶性NHL因复发率
Autologous stem cell transplantation (AHSCT) for the treatment of malignant lymphoma was first reported in 1978. Currently, peripheral blood stem cell transplantation (PBSCT) is becoming the mainstream of AHSCT. Because PBSCT is superior to bone marrow transplantation (ABMT) in terms of safety and medical expenses. AHSCT was used for moderately malignant non-Hodgkin’s lymphoma (NHL). It was reported that the first remission (CR_1) had a disease-free survival rate (DFS) of 55% to 80%, and the DFS for sensitive relapse of chemotherapy was 30% to 50%. The chemotherapy-insensitive group DFS was below 15%. The authors reviewed 33 cases of moderate-malignant NHL in the Fukuoka bone marrow transplantation group and performed PBSCT, including CR_1 9 cases, CR_2 8 cases, relapse/chemotherapy insensitive 16 cases, and 2 years DFS were 75%, 49%, and 33%, respectively. Effect. Highly malignant NHL due to recurrence rate